Published On: Wed, Oct 19th, 2016

Latest Analyst Reports On Integra LifeSciences Holdings Corporation


Recently stock market analysts have updated their consensus ratings on shares of Integra LifeSciences Holdings Corporation (NASDAQ:IART).

Most recent broker ratings

10/04/2016 – Integra LifeSciences Holdings Corporation had its “outperform” rating reiterated by analysts at Oppenheimer. They now have a USD 93 price target on the stock.

09/26/2016 – Integra LifeSciences Holdings Corporation had its “buy” rating reiterated by analysts at Jefferies. They now have a USD 95 price target on the stock.

09/23/2016 – Integra LifeSciences Holdings Corporation had its “buy” rating reiterated by analysts at Argus. They now have a USD 105 price target on the stock.

08/19/2016 – Integra LifeSciences Holdings Corporation had its “overweight” rating reiterated by analysts at Piper Jaffray. They now have a USD 94 price target on the stock.

07/29/2016 – Integra LifeSciences Holdings Corporation had its “equal weight” rating reiterated by analysts at Barclays. They now have a USD 84 price target on the stock.

07/13/2016 – Integra LifeSciences Holdings Corporation had its “overweight” rating reiterated by analysts at JP Morgan.

11/12/2015 – Citigroup began new coverage on Integra LifeSciences Holdings Corporation giving the company a “buy” rating. They now have a USD 75 price target on the stock.

09/21/2015 – Integra LifeSciences Holdings Corporation was upgraded to “buy” by analysts at Bank of America Merrill Lynch. They now have a USD 79 price target on the stock.

08/26/2015 – Integra LifeSciences Holdings Corporation had its “hold” rating reiterated by analysts at Lake Street. They now have a USD 55 price target on the stock.

07/29/2015 – Integra LifeSciences Holdings Corporation was upgraded to “outperform” by analysts at Raymond James.

05/05/2015 – Integra LifeSciences Holdings Corporation was upgraded to “buy” by analysts at Zacks. They now have a USD 73 price target on the stock.

05/04/2015 – Integra LifeSciences Holdings Corporation was upgraded to “outperform” by analysts at Wells Fargo.

05/04/2015 – Integra LifeSciences Holdings Corporation had its “sector perform” rating reiterated by analysts at RBC Capital. They now have a USD 66 price target on the stock.

02/27/2014 – Integra LifeSciences Holdings Corporation had its “” rating reiterated by analysts at SunTrust. They now have a USD 43 price target on the stock.

11/11/2013 – Integra LifeSciences Holdings Corporation was upgraded to “equal weight” by analysts at Morgan Stanley. They now have a USD 40 price target on the stock.

Integra LifeSciences Holdings Corporation has a 50 day moving average of 84.59 and a 200 day moving average of 78.31. The stock’s market capitalization is 3.05B, it has a 52-week low of 54.75 and a 52-week high of 88.86.

The share price of the company (NASDAQ:IART) was up +1.09%, with a high of 81.96 during the day and the volume of Integra LifeSciences Holdings Corporation shares traded was 290440.

Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing and marketing of surgical implants and medical instruments. Its products are used in neurosurgery, extremity reconstruction, orthopedics and general surgery. Its segments include Specialty Surgical Solutions, which offers products, including specialty surgical instrumentation for a range of specialties. Its product category includes products and solutions for dural repair, precision tools and instruments, tissue ablation and neuro critical care, including product portfolios used in neurosurgery operation suites and critical care units, and Orthopedics and Tissue Technologies, which offers products of a combination of differentiated regenerative technology products for soft tissue repair and tissue regeneration products, and small bone fixation and joint replacement hardware products for both upper extremities and lower extremities.